Skip to main content

"A new methodology based on an advanced molecular probe for early detection of DPD enzyme deficiency in oncological patients, also enabling a personalised and effective drug management"

Objectif

"Amongst all the chemotherapy agents, 5-FU (fluorouracil) is being in use since 40 years, and is one of the most successful and widely employed in the treatment for breast, colon, and skin cancer, three of the most frequently occurring malignant tumours. In general, 5-FU is relatively well tolerated at standard doses, but there are some important issues that must be duly taken into consideration: 1)Around 8% of patients manifest a genetic variation that leads to a deficiency of an enzyme called Dihydropyrimidine dehydrogenase (DPD) that is crucial for the metabolism and deactivation of 5-FU. This causes several toxic reactions like mucositis, diarrhea, neutropenia, cerebellar ataxia, cerebellar dysfunction, and can even be fatal at the very first dose of 5-FU, with a mortality rate of about 0,5%. About 30% of patients suffer from severe toxicity effects after being treated with 5FU. Despite many approaches have been proposed for DPD deficiency screening, none of the current strategies are adequate to mandate routine DPD testing prior to starting a 5-FU based therapy. The CARESS project proposes to implement the first, compact, cheap, accurate and standard system for measuring the DPD activity level, thus allowing for fast screening of DPD deficiency and for real time adjusting the therapy administered to the patient through a pharmacokinetic approach, allowing to maximise the therapeutic efficacy, abating the costs associated to the management of the therapy and, most importantly, to limit the dangerous side effects for the patients. The system will take as input a small blood sample and will rely on the chemical interaction between a 5-FU analogous chemical probe with the sample, which will release in the solution ions that can be easily detected and measured through optical analysis."

Champ scientifique

  • /sciences sociales/sociologie/démographie/mortalité
  • /sciences médicales et de la santé/médecine clinique/oncologie/cancer/cancer du sein
  • /sciences médicales et de la santé/médecine clinique/oncologie/cancer/cancer de la peau

Appel à propositions

FP7-SME-2012
Voir d’autres projets de cet appel

Régime de financement

BSG-SME - Research for SMEs

Coordinateur

IRBM SCIENCE PARK SPA
Adresse
Via Pontina Km 30600
00040 Pomezia Rm
Italie
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contribution de l’UE
€ 410 611,50
Contact administratif
Maria Pace Napoleone (Dr.)

Participants (6)

ODPM SAS
France
Contribution de l’UE
€ 257 048
Adresse
Rue Moll 2
49933 Angers
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact administratif
Sophie Signorelli (Ms.)
Optomesures
France
Contribution de l’UE
€ 197 152
Adresse
Enceinte Serres
31590 Saint Marcel Paulel
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact administratif
Bernard Genot (Mr.)
AMEDA Labordiagnostik GmbH
Autriche
Contribution de l’UE
€ 291 148,50
Adresse
Krenngasse 12
8010 Graz
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact administratif
Gerald Herfort (Mr.)
CONSIGLIO NAZIONALE DELLE RICERCHE
Italie
Adresse
Piazzale Aldo Moro 7
00185 Roma
Type d’activité
Research Organisations
Contact administratif
Aldo Rosati (Mr.)
INSTITUT DE CANCEROLOGIE DE L'OUEST
France
Adresse
15 Rue Andre Boquel, Cs10059
49100 Angers
Type d’activité
Research Organisations
Contact administratif
Catherine Romefort (Ms.)
LABOR SRL
Italie
Adresse
Via Della Scrofa 117
00186 Roma
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact administratif
Cristina Torrisi (Dr.)